The SLC22A24 antibody is a research tool designed to detect and study the solute carrier family 22 member 24 (SLC22A24) protein, a relatively undercharacterized transporter within the SLC22 family. This family encompasses membrane proteins involved in the transport of endogenous compounds, xenobiotics, and drugs across cellular membranes, primarily in excretory organs like the kidney and liver. SLC22A24. though less studied compared to other members (e.g., SLC22A1/OCT1 or SLC22A6/OAT1), is hypothesized to play roles in organic anion/cation transport, potentially influencing drug disposition, detoxification, or metabolic pathways. Its expression patterns, substrate specificity, and physiological relevance remain areas of active investigation.
The SLC22A24 antibody is typically developed for applications such as Western blotting, immunohistochemistry, or immunofluorescence to localize the protein in tissues or assess its expression levels under varying conditions. Its utility lies in elucidating SLC22A24's tissue distribution, regulatory mechanisms, and involvement in disease contexts, such as renal dysfunction, metabolic disorders, or drug resistance. Validation of antibody specificity (e.g., via knockout controls) is critical due to potential cross-reactivity within the SLC22 family. Research using this antibody aims to clarify SLC22A24's biological and pharmacological significance, bridging gaps in understanding solute carrier biology and therapeutic targeting.